GnRH-a-1M

PreclinicalSmall molecule

FFirst Affiliated Hospital, Sun Yat-Sen University

GnRH-a-1M is one of 12 small molecule programs targeting Adenomyosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenomyosisActive, not recruiting

AdenomyosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Adenomyosis

#DrugCompanyPhaseTrials

Bayer Aspirin

Femara

Zoladex

TTerSera Therapeutics LLC

Ofev

1 5

Prometrium

Ferring

Phase 3

1 6

Dienogest

Bayer

Phase 3

4 7

Trelstar

OOncoVerity, Inc.

Preclinical

1 8

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

1 9

Drospirenone

EExeltis France

Preclinical

1 10

LNG-IUS

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Adenomyosis

NCT07065539

Clinical

Trials by Indication[1]

Adenomyosis1 trial

GnRH Agonist Pretreatment Duration and Letrozole Supplementation in Frozen Embryo Transfer for Adenomyosis Patients

Not yet recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·N/A·NCT07065539·432 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GnRH-a-1M. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GnRH-a-1M compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GnRH-a-1M. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital, Sun Yat-Sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFirst Affiliated Hospital, Sun Yat-Sen University

GnRH-a-1M

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Adenomyosis1 trial

References

Drug Info

Quick Facts

Related News